HRS-1893 (also known as BHB-1893) is a selective, small-molecule, cardiac myosin inhibitor engineered to improve heart performance in patients with HCM. By modulating cardiac contractility, HRS-1893 ...
How Thousands of Small, Community-Embedded Micro-Schools Will Cut Education Costs by 70% and Close Nigeria’s Access Gap By ...
Metabolic will be the first provider outside the United States to offer the new treatment, within weeks of the FDA’s approval ...
Most Americans fall short of fiber targets. Here’s how to help people understand how much they need — and how to get higher ...
Defensive healthcare stocks such as Johnson & Johnson and CVS tend to outperform in recessions. Growth healthcare stocks ...
Combat veterans fight for recognition and care, while a new drug emerges as a possible solution for PTSD.
The Quiet Lab Mouthpiece Uses Precision Adjustment to Stop Snoring at the Source, Helping Partners Return ...
Biomea Fusion, Inc. ( BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes March 30, 2026 3:00 PM EDT Michael J. Hitchcock - Interim CEO & Director Ramses Erdtmann - ...
A pivotal step in PharmaEssentia's dual-site U.S.-Taiwan manufacturing strategy, with 2027 operations in sight ...
Orforglipron is the first new molecular entity cleared under the FDA's Commissioner's National Priority Voucher (CNPV) pilot ...
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population; Phase 1b data demonstrate ...
Overwhelming waiting lists make the headlines, but what needs to change on a societal level?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results